DE60033241T2 - Kompositionen und verfahren zum nachweis von treponema pallidum - Google Patents
Kompositionen und verfahren zum nachweis von treponema pallidum Download PDFInfo
- Publication number
- DE60033241T2 DE60033241T2 DE60033241T DE60033241T DE60033241T2 DE 60033241 T2 DE60033241 T2 DE 60033241T2 DE 60033241 T DE60033241 T DE 60033241T DE 60033241 T DE60033241 T DE 60033241T DE 60033241 T2 DE60033241 T2 DE 60033241T2
- Authority
- DE
- Germany
- Prior art keywords
- treponema pallidum
- pallidum
- antibody
- peptide
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000589884 Treponema pallidum Species 0.000 title claims abstract description 136
- 238000000034 method Methods 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 title abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 175
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 160
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 116
- 208000006379 syphilis Diseases 0.000 claims abstract description 75
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 57
- 230000002378 acidificating effect Effects 0.000 claims abstract description 49
- 238000001514 detection method Methods 0.000 claims abstract description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 28
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 201000009482 yaws Diseases 0.000 claims abstract 3
- 150000001413 amino acids Chemical class 0.000 claims description 65
- 230000002163 immunogen Effects 0.000 claims description 64
- 239000012472 biological sample Substances 0.000 claims description 20
- 239000007790 solid phase Substances 0.000 claims description 18
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 230000001014 anti-treponemal effect Effects 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 206010052428 Wound Diseases 0.000 claims 1
- 210000001124 body fluid Anatomy 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 210000003756 cervix mucus Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000000582 semen Anatomy 0.000 claims 1
- 210000001138 tear Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 43
- 230000000890 antigenic effect Effects 0.000 abstract description 22
- 208000035055 Treponemal Infections Diseases 0.000 abstract description 12
- 208000025884 Treponema infectious disease Diseases 0.000 abstract description 9
- 208000009090 primary syphilis Diseases 0.000 abstract description 9
- 201000003595 bejel Diseases 0.000 abstract description 8
- 241000589886 Treponema Species 0.000 abstract description 6
- 238000003556 assay Methods 0.000 abstract description 4
- 206010044587 Treponema infections Diseases 0.000 abstract 1
- 231100000676 disease causative agent Toxicity 0.000 abstract 1
- 238000011896 sensitive detection Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 146
- 235000001014 amino acid Nutrition 0.000 description 43
- 229940024606 amino acid Drugs 0.000 description 43
- 239000000126 substance Substances 0.000 description 25
- 239000000427 antigen Substances 0.000 description 21
- 102000036639 antigens Human genes 0.000 description 21
- 108091007433 antigens Proteins 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 239000000523 sample Substances 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 239000012634 fragment Substances 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 238000003745 diagnosis Methods 0.000 description 16
- 230000006378 damage Effects 0.000 description 13
- 238000003018 immunoassay Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 210000004379 membrane Anatomy 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 239000011324 bead Substances 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 101150099865 arp gene Proteins 0.000 description 8
- 208000003796 chancre Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- 231100000397 ulcer Toxicity 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 208000012886 Vertigo Diseases 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 231100000889 vertigo Toxicity 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 208000002040 neurosyphilis Diseases 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 102000004895 Lipoproteins Human genes 0.000 description 5
- 108090001030 Lipoproteins Proteins 0.000 description 5
- 238000009534 blood test Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 108010033276 Peptide Fragments Proteins 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 201000000860 Secondary syphilis Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 206010056873 tertiary syphilis Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N Glutamine Chemical compound OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000003748 differential diagnosis Methods 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108010087967 type I signal peptidase Proteins 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005266 casting Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 201000006901 congenital syphilis Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007885 magnetic separation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- STMWFYZHRFYDPA-UHFFFAOYSA-N 2-[[4-[1-(2,4-diaminopteridin-6-yl)ethylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1C(C)NC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 STMWFYZHRFYDPA-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101800000112 Acidic peptide Proteins 0.000 description 1
- 101800000263 Acidic protein Proteins 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 101100056767 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arp-3 gene Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001295 alanines Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000004904 long-term response Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030247 mild fever Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000026843 stiff neck Diseases 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000037997 venous disease Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Cosmetics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13898199P | 1999-06-14 | 1999-06-14 | |
| US138981P | 1999-06-14 | ||
| PCT/US2000/016425 WO2000077486A2 (en) | 1999-06-14 | 2000-06-14 | Compositions and methods for detecting treponema pallidum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60033241D1 DE60033241D1 (de) | 2007-03-22 |
| DE60033241T2 true DE60033241T2 (de) | 2007-11-15 |
Family
ID=22484572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60033241T Expired - Fee Related DE60033241T2 (de) | 1999-06-14 | 2000-06-14 | Kompositionen und verfahren zum nachweis von treponema pallidum |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7005270B2 (https=) |
| EP (1) | EP1240519B1 (https=) |
| JP (1) | JP2003510559A (https=) |
| CN (1) | CN1185255C (https=) |
| AT (1) | ATE353137T1 (https=) |
| AU (1) | AU775526B2 (https=) |
| BR (1) | BR0011624A (https=) |
| CA (1) | CA2375924A1 (https=) |
| DE (1) | DE60033241T2 (https=) |
| WO (1) | WO2000077486A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000077486A2 (en) * | 1999-06-14 | 2000-12-21 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Compositions and methods for detecting treponema pallidum |
| JP3883934B2 (ja) * | 2002-08-29 | 2007-02-21 | 富士フイルムホールディングス株式会社 | 生化学解析用ユニットを利用した化学発光法 |
| WO2007066731A1 (ja) * | 2005-12-07 | 2007-06-14 | Sekisui Medical Co., Ltd. | 抗リン脂質抗体測定試薬及び抗トレポネーマ・パリダム抗体測定試薬 |
| JP4629563B2 (ja) * | 2005-12-07 | 2011-02-09 | 積水メディカル株式会社 | 抗リン脂質抗体測定試薬 |
| CN101858914B (zh) * | 2010-05-19 | 2013-03-27 | 厦门大学附属中山医院 | 梅毒特异性总抗体胶体金免疫层析检测试剂条及其制备方法 |
| RU2474820C2 (ru) * | 2011-04-11 | 2013-02-10 | Виктория Олеговна Пожарская | Способ контроля эффективности лечения сифилиса |
| US8945827B2 (en) | 2013-03-13 | 2015-02-03 | Awareness Technology, Inc. | Serological methods and diagnostic tests for syphilis antibodies |
| CN111593132B (zh) * | 2020-06-09 | 2024-07-05 | 柯吴坚 | 一种基于tp0136基因异质性用于区分梅毒螺旋体不同亚型的分子分型方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4738932A (en) * | 1985-12-03 | 1988-04-19 | Advanced Polymer Systems, Inc. | Reaginic test for syphilis |
| US4894328A (en) * | 1986-03-26 | 1990-01-16 | Board Of Regents, The University Of Texas System | Immunodiagnostic test for syphilis and other treponemal infections |
| US5965702A (en) * | 1991-10-21 | 1999-10-12 | Abbott Laboratories | Borrelia burgdorferi antigens and uses thereof |
| US5330754A (en) * | 1992-06-29 | 1994-07-19 | Archana Kapoor | Membrane-associated immunogens of mycobacteria |
| GB9314011D0 (en) * | 1993-07-07 | 1993-08-18 | Porton Cambridge Ltd | New diagnostic assay for detection of syphilis |
| US5753459A (en) * | 1994-01-06 | 1998-05-19 | The Regents Of The University Of California | Nucleotide sequences of T. pallidum rare outer membrane protein |
| WO2000077486A2 (en) * | 1999-06-14 | 2000-12-21 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Compositions and methods for detecting treponema pallidum |
-
2000
- 2000-06-14 WO PCT/US2000/016425 patent/WO2000077486A2/en not_active Ceased
- 2000-06-14 CN CNB008089426A patent/CN1185255C/zh not_active Expired - Fee Related
- 2000-06-14 AT AT00941424T patent/ATE353137T1/de not_active IP Right Cessation
- 2000-06-14 EP EP00941424A patent/EP1240519B1/en not_active Expired - Lifetime
- 2000-06-14 JP JP2001503496A patent/JP2003510559A/ja active Pending
- 2000-06-14 CA CA002375924A patent/CA2375924A1/en not_active Abandoned
- 2000-06-14 AU AU56131/00A patent/AU775526B2/en not_active Ceased
- 2000-06-14 BR BR0011624-6A patent/BR0011624A/pt not_active IP Right Cessation
- 2000-06-14 DE DE60033241T patent/DE60033241T2/de not_active Expired - Fee Related
-
2001
- 2001-12-14 US US10/017,168 patent/US7005270B2/en not_active Expired - Fee Related
-
2005
- 2005-09-06 US US11/221,263 patent/US7335736B2/en not_active Expired - Fee Related
-
2007
- 2007-12-26 US US11/964,552 patent/US20080139783A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003510559A (ja) | 2003-03-18 |
| ATE353137T1 (de) | 2007-02-15 |
| BR0011624A (pt) | 2002-06-11 |
| US7005270B2 (en) | 2006-02-28 |
| EP1240519A2 (en) | 2002-09-18 |
| AU5613100A (en) | 2001-01-02 |
| CN1185255C (zh) | 2005-01-19 |
| US7335736B2 (en) | 2008-02-26 |
| WO2000077486A2 (en) | 2000-12-21 |
| DE60033241D1 (de) | 2007-03-22 |
| HK1050728A1 (en) | 2003-07-04 |
| CA2375924A1 (en) | 2000-12-21 |
| US20050191712A1 (en) | 2005-09-01 |
| US20060051823A1 (en) | 2006-03-09 |
| US20080139783A1 (en) | 2008-06-12 |
| EP1240519B1 (en) | 2007-01-31 |
| AU775526B2 (en) | 2004-08-05 |
| WO2000077486A3 (en) | 2002-07-11 |
| CN1399722A (zh) | 2003-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60108256T2 (de) | Allergen-microarray-test | |
| Deplazes et al. | An enzyme-linked immunosorbent assay for diagnostic detection of Taenia saginata copro-antigens in humans | |
| DE69607176T2 (de) | Verfahren zur quantitativen bestimmung menschlichen akutphasen-serum-amyloid-a-proteins; rekombinantes protein; spezifischer antikörper | |
| DE60016275T2 (de) | Helicobacter pylori antigene in blut | |
| DE19649390A1 (de) | Antigenspezifischer IgG-Nachweis | |
| DE60025605T2 (de) | Synthetische antigene zum nachweis von syphilis | |
| US20080139783A1 (en) | Compositions and methods for detecting treponema pallidum | |
| KR100951057B1 (ko) | 면역특이단백질 항원을 사용하는 우결핵 특이 효소면역진단키트 및 이를 이용한 우결핵 진단방법 | |
| DE69619405T2 (de) | Verbindungen und verfahren zum nachweis und zur vorbeugung von t.cruzi infektionen | |
| EP0918865B1 (de) | Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe | |
| DE69909897T2 (de) | Nachweis von Antikörpern gegen FIV unter Benutzung von ENV/GAG Polypeptiden | |
| DE69934098T2 (de) | Neues diagnostisches reagens und kit zur erkennung von rickettsiose | |
| DE10101792B4 (de) | Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern | |
| WO2023138893A1 (de) | Test zum nachweis von antikörpern-gegen leishmanien | |
| DE60014616T2 (de) | Antikörper gegen plazentaprotein 13 | |
| Ibrahim et al. | Categorization of venoms according to bonding properties: An immunological overview | |
| DE69400936T2 (de) | Peptid entsprechend einem Epitop des menschlichen Parvovirus B19 | |
| DE3879055T2 (de) | Die sm-b/b1-antigene, das klonen der sm-b/b1-antigene und der nachweis von systemischem lupus erythematosus unter verwendung der sm b/b1-antigene. | |
| DE602004004312T2 (de) | Allergenes Kautschuk-Protein | |
| EP2288920B1 (de) | Verfahren zur bestimmung von trichinella-infektionen | |
| DE29880124U1 (de) | Diagnostische Kit zum Nachweis von Borna-Disease-Virus (BDV)-Infektionen über den Nachweis zirkulierender Immunkomplexe | |
| DE10207135A1 (de) | Verfahren und Kit zum Nachweis von spezifischen Antikörpern mittels Immunfluoreszenz | |
| Jones et al. | Elevated serum antibody responses to synthetic mycobacterial lipid antigens among UK farmers: an indication of exposure to environmental mycobacteria? | |
| EP3682242A1 (de) | Verfahren zum nachweis akuter borna disease virus (bdv) infektionen und eines diagnostischen kits hierfür, insbesondere in kombination mit verfahren zur unterscheidung akuter von chronischen und ruhenden bdv-infektionen und diagnostische kits hierfür | |
| DE69201463T2 (de) | Diagnostisches Verfahren. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |